A DRUG which extends the lives of patients who are dying from skin cancer has been approved for use on the NHS in England – but rejected in Scotland.
The National Institute for Health and Clinical Excellence has backed the use of Zelboraf in appropriate melanona patients, two months after it was turned down by the Scottish Medicines Consortium (SMC).
Charities, cancer clinicians and drugs companies have all raised concern that patients north of the Border are increasingly unable to access new treatments which are prescribed in England and Wales.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
